Warfarin vs. Asprin in Reduced Ejection Fraction
Warfarin vs. Asprin in Reduced Ejection Fraction
Warfarin vs. Asprin in Reduced Ejection Fraction
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Primary Aim<br />
To determ<strong>in</strong>e if warfar<strong>in</strong> or aspir<strong>in</strong> is superior for<br />
prevent<strong>in</strong>g comb<strong>in</strong>ed outcome of death, ischemic<br />
stroke, or <strong>in</strong>tracerebral hemorrhage <strong>in</strong> patients with<br />
LVEF ≤ 35% <strong>in</strong> s<strong>in</strong>us rhythm<br />
Ma<strong>in</strong> Secondary Aim<br />
To determ<strong>in</strong>e if warfar<strong>in</strong> or aspir<strong>in</strong> is superior for<br />
prevent<strong>in</strong>g comb<strong>in</strong>ed outcome of death, ischemic<br />
stroke, <strong>in</strong>tracerebral hemorrhage, MI, or heart<br />
failure hospitalization <strong>in</strong> patients with LVEF ≤ 35%<br />
<strong>in</strong> s<strong>in</strong>us rhythm
Change language